Headquartered in Carlsbad, CA Fiscal year ends December NASDAQ: DSGN designtx.com
Design Therapeutics is a clinical-stage biotechnology company developing a new class of therapies based on its GeneTAC (gene targeted chimera) small molecule platform. The company's GeneTAC molecules are designed to either increase or decrease the expression of specific disease-causing genes to address the underlying cause of genetic diseases. Design Therapeutics has three clinical-stage programs: DT-216P2 for Friedreich ataxia, DT-168 for Fuchs endothelial corneal dystrophy, and DT-818 for myotonic dystrophy type 1. The company is also advancing a preclinical program in Huntington's disease and has discovery-stage efforts for multiple additional genomic medicines. The company is pre-revenue and trades on the Nasdaq exchange. Updated
An EV maker on the rebound, a Sun Belt landlord facing fresh headwinds, and a clinical-stage biotech sitting on pivotal pipeline data have all landed on analysts' radars this week for very…
Pre-Market Stock Futures: The futures are trading higher after NVIDIA Inc. (NASDAQ: NVDA | NVDA Price Prediction) blew out its fiscal third-quarter results and offered strong forward guidance, though perhaps not as…
Design Therapeutics is a clinical-stage biotechnology company developing a new class of therapies based on its GeneTAC (gene targeted chimera) small molecule platform.
The Wall Street consensus 12-month price target for DSGN is $21.71.
